Article
Oncology
Er Yue, Guangchao Yang, Yuanfei Yao, Guangyu Wang, Atish Mohanty, Fang Fan, Ling Zhao, Yanqiao Zhang, Tamara Mirzapoiazova, Tonya C. Walser, Lorna Rodriguez-Rodriguez, Yuman Fong, Ravi Salgia, Edward Wenge Wang
Summary: Ovarian cancer is a deadly disease with urgent need for new treatments. The development of a conditionally replicative oncolytic adenovirus (CRAd) that targets MUC16/CA-125 in cancer cells shows promising anti-cancer effects. This approach represents a unique and practical direction for further investigation in ovarian cancer treatment.
Article
Chemistry, Multidisciplinary
Julian Matthias Metzler, Daniel Fink, Patrick Imesch
Summary: Ibrutinib, a small-molecule inhibitor of Bruton's tyrosine kinase, is used to treat hematological diseases like chronic lymphocytic leukemia. The hypothesis that it may suppress the tumor marker CA-125 in ovarian cancer is based on an observation in a patient with low-grade serous ovarian cancer who received ibrutinib for CLL. A mechanistic model explaining this potential drug effect is proposed for further research.
APPLIED SCIENCES-BASEL
(2021)
Review
Oncology
Qingyi Wang, Xiaoling Feng, Xiaofang Liu, Siyu Zhu
Summary: According to the meta-analysis, higher pretreatment serum CA-125 levels are associated with poor prognosis in epithelial ovarian cancer (EOC) patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Olivier Colomban, Elizabeth M. Swisher, Rebecca Kristeleit, Iain McNeish, Ronnie Shapira-Frommer, Sandra Goble, Kevin K. Lin, Lara Maloney, Gilles Freyer, Benoit You
Summary: Mathematical modeling of early CA-125 kinetics can be used as an indicator of rucaparib efficacy in recurrent ovarian carcinoma patients. The KELIM-PARP score is associated with treatment response and progression-free survival. This study suggests the potential use of this strategy in selecting patients for PARPi-based treatment regimens.
Article
Biochemical Research Methods
Jin Song, Lori J. J. Sokoll, Zhen Zhang, Daniel W. W. Chan
Summary: Close to 75% of ovarian cancer cases are diagnosed at an advanced stage, with a high rate of relapse after primary therapy. Therefore, it is crucial to identify strategies for early detection of ovarian cancer recurrence to improve outcomes.
CLINICAL PROTEOMICS
(2023)
Article
Immunology
Lingeng Lu, Wenxue Ma, Caroline H. Johnson, Sajid A. Khan, Melinda L. Irwin, Lajos Pusztai
Summary: Somatic mutation-derived neoantigens are used to develop an mRNA vaccine targeting CA-125 neoantigen for breast and ovarian cancer. Immuno-bioinformatics tools were used to predict CD8' T cell epitopes and a self-adjuvant mRNA vaccine was constructed to enhance cross-presentation by dendritic cells. Immune responses post-immunization were estimated using an in silico algorithm, showing IFN-c and CD8' T cell response. The strategy described in this study can be used to design precision multi-epitope mRNA vaccines targeting multiple neoantigens.
Article
Oncology
Christoph Wohlmuth, Vladimir Djedovic, Susanne K. Kjaer, Allan Jensen, Rosalind Glasspool, Patricia Roxburgh, Anna DeFazio, Sharon E. Johnatty, Penelope M. Webb, Francesmary Modugno, Diether Lambrechts, Joellen M. Schildkraut, Andrew Berchuck, Liv Cecilie Vestrheim Thomsen, Line Bjorge, Estrid Hogdall, Claus K. Hogdall, Ellen L. Goode, Stacey J. Winham, Keitaro Matsuo, Beth Y. Karlan, Jenny Lester, Marc T. Goodman, Pamela J. Thompson, Tanja Pejovic, Marjorie J. Riggan, Katherine Lajkosz, Alicia Tone, Taymaa May
Summary: This study analyzed data from 176 women with low-grade serous ovarian cancer through a multi-center collaborative effort, revealing that elevated post-treatment CA-125 levels are significantly associated with poor survival, while FIGO staging and residual disease also impact patient outcomes.
Article
Chemistry, Analytical
Omer Faruk Er, Hilal Kivrak, Omruye Ozok, Sebahattin Celik, Arif Kivrak
Summary: The COVID-19 crisis has a serious impact on ovarian cancer patients, highlighting the importance of early detection. In this study, a PTTC-based sensor was designed to detect CA-125, a common marker for ovarian cancer, with higher precision and speed using electrochemical methods. The PTTC-based GCE electrode showed promising sensitivity and reliability for CA-125 detection, with optimum conditions determined as 3 μL PTTC loading, 5000 ng/mL CA125 antigen concentration, and 30 min incubation time. The linear range of this electrode was found to be 1-100 ng/mL, with a limit of detection of 0.0096 ng/mL and a limit of quantification of 0.0288 ng/mL. These findings suggest that PTTC is a novel and promising material for the detection of ovarian cancer antigen CA-125.
JOURNAL OF ELECTROANALYTICAL CHEMISTRY
(2022)
Article
Multidisciplinary Sciences
Szymon Piatek, Grzegorz Panek, Zbigniew Lewandowski, Dominika Piatek, Przemyslaw Kosinski, Mariusz Bidzinski
Summary: The nadir CA-125 level in patients with epithelial ovarian cancer is associated with progression-free survival but not overall survival. Patients with nadir CA-125 levels between 11-35 U/ml after first-line treatment have a higher risk of recurrence compared to patients with levels <= 10 U/ml.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Juhun Lee, Jong Mi Kim, Yoon Hee Lee, Gun Oh Chong, Dae Gy Hong
Summary: This study analyzed the relationship between serum CA-125 levels after chemotherapy and clinical outcomes in Korean women with epithelial ovarian cancer. The results showed that serum CA-125 is correlated with clinical outcomes and can be used to predict platinum resistance in ovarian cancer treatment.
ANTICANCER RESEARCH
(2022)
Article
Oncology
Benoit You, Christopher Purdy, Larry J. Copeland, Elizabeth M. Swisher, Michael A. Bookman, Gini Fleming, Robert Coleman, Leslie M. Randall, Krishnansu S. Tewari, Bradley J. Monk, Robert S. Mannel, Joan L. Walker, Fabio Cappuccini, David Cohn, Mahvish Muzaffar, David Mutch, Andrea Wahner-Hendrickson, Lainie Martin, Olivier Colomban, Robert A. Burger
Summary: In patients with high-grade ovarian cancer, only those with high-risk disease and poor tumor chemosensitivity benefit from bevacizumab treatment, suggesting that bevacizumab may be prioritized for these patients.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Nattinee Krathumkhet, Toyoko Imae, Fu-ming Wang, Chiou-Chung Yuan, Jusni Manidae Lumban Gaol, Nophawan Paradee
Summary: In this study, a novel cancer antigen 125 (CA125) biomarker detection method based on electro-chemical immunosensor was demonstrated. The biomarker on conductive composite materials of carbon ink/carbon dot/zinc oxide (C-ink/CD/ZnO) was used as an electrode platform, enhancing the interaction of antibodies (Ab) with the catalytic performance of ZnO. The created immunosensor showed a wide linear range and low detection limit, making it an accurate and efficient diagnostic tool for CA125 and other biomarkers in clinical sample analysis.
BIOELECTROCHEMISTRY
(2023)
Article
Oncology
Roli Purwar, Kishan Soni, Ragini Tilak, Ashish Verma, Manoj Pandey
Summary: Peritonitis associated with Curvularia lunata is rare, with only five cases reported in the literature, all in middle-aged patients with comorbidities undergoing dialysis. This case report presents a 21-year-old female patient who was diagnosed with ovarian malignancy based on raised CA 125 and suspected tubo-ovarian mass on MRI, but was later found to have a pelvic collection with Curvularia lunata infection.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Syamel Muhammad, Reyhan Julio Azwan, Rauza Sukma Rita, Restu Susanti, Yusrawati
Summary: This study investigates the predictive role of IL6, CA-125, and HE4 in tumor resectability in pre-operative patients with advanced epithelial ovarian cancer and finds a correlation between these markers and tumor resectability.
Review
Chemistry, Analytical
Mehrab Pourmadadi, Ali Moammeri, Amin Shamsabadipour, Yasamin Farahanian Moghaddam, Abbas Rahdar, Sadanand Pandey
Summary: Diagnosing early-stage cancers is crucial for saving lives and reducing mortality rates. Detection of the cancer antigen CA-125 is a key step in the treatment of certain cancers, such as ovarian cancer. This review discusses various optical and electrochemical methods for detecting CA-125, compares their performance and sensitivity, investigates commercial detection kits, and evaluates their applicability and accuracy.
Article
Oncology
Florian Fanget, Amaniel Kefleyesus, Julien Peron, Isabelle Bonnefoy, Laurent Villeneuve, Guillaume Passot, Pascal Rousset, Benoit You, Nazim Benzerdjeb, Olivier Glehen, Vahan Kepenekian
Summary: In this retrospective study, a FOLFIRINOX regimen as NACT seemed to result in better long-term outcomes for CRPM patients after complete CRS/HIPEC, although with higher morbidity.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Pauline Corbaux, Catherine Terret, Claire Cropet, Sylvie Chabaud, Chiara Russo, Christelle Faure, Olivier Tredan, Thomas Bachelot, Pierre-Etienne Heudel
Summary: This study aimed to examine the effect of additional chemotherapy on overall survival in patients aged 70 years or older with early breast cancer, as well as the impact of comorbidities on chemotherapy benefit. The results showed that additional chemotherapy was associated with improved overall survival, while chronic obstructive pulmonary disease and polypharmacy were associated with worse overall survival. These findings support the importance of chemotherapy considerations in elderly patients with early breast cancer.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Madeleine Maugeais, Julien Peron, Stephane Dalle, Amelie Boespflug, Michael Duruissaux, Pauline Corbaux, Thibault Reverdy, Gulsum Sahin, Aurelie Rabier, Jonathan Lopez, Nathalie Freymond, Denis Maillet
Summary: The presence of liver metastases (LM) and the number of metastatic sites (MS) have an impact on the survival outcomes of patients treated with single-agent anti-PD(L)1. LM is associated with shorter progression-free survival (PFS) and overall survival (OS). Patients with multiple MS also have poorer clinical outcomes. Therefore, LM and MS number are independent prognostic factors for patients treated with anti-PD(L)1.
Article
Medicine, General & Internal
Peter H. Cashin, Jesus Esquivel, Stein G. Larsen, Winston Liauw, Nayef A. Alzahrani, David L. Morris, Vahan Kepenekian, Isabelle Sourrouille, Frederic Dumont, Jean-Jacques Tuech, Cecilia Ceribelli, Beranger Doussot, Olivia Sgarbura, Francois Quenet, Olivier Glehen, Oliver M. Fisher
Summary: This study aimed to evaluate the effects of neoadjuvant and adjuvant systemic therapy in patients with colorectal cancer peritoneal metastases undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The study found that neoadjuvant therapy did not significantly improve the survival period for patients, while adjuvant therapy was associated with a benefit in terms of survival.
Editorial Material
Oncology
Frederic Schell, Amaniel Kefleyesus, Nazim Benzerdjeb, Guillaume Passot, Pascal Rousset, Alhadeedi Omar, Laurent Villeneuve, Julien Peron, Olivier Glehen, Vahan Kepenekian
ANNALS OF SURGICAL ONCOLOGY
(2023)
Editorial Material
Oncology
Vahan Kepenekian, Amaniel Kefleyesus, Guillaume Passot, Pascal Rousset, Nazim Benzerdjeb, Benoit You, Julien Peron, Olivier Glehen
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Frederic Schell, Amaniel Kefleyesus, Nazim Benzerdjeb, Guillaume Passot, Pascal Rousset, Alhadeedi Omar, Laurent Villeneuve, Julien Peron, Olivier Glehen, Vahan Kepenekian
Summary: In patients with colorectal cancer peritoneal metastasis, limited extraperitoneal disease involving one site, notably the liver, does not significantly impair postoperative results. However, lymph node invasion is a poor prognostic factor in this population.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Editorial Material
Oncology
Florian Fanget, Amaniel Kefleyesus, Julien Peron, Isabelle Bonnefoy, Laurent Villeneuve, Guillaume Passot, Pascal Rousset, Benoit You, Nazim Benzerdjeb, Olivier Glehen, Vahan Kepenekian
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Pamela Funk-Debleds, Julien Rossi, Lorraine Bernard, Alexandre Galan, Vahan Kepenekian, Olivier Glehen, Cecile Chambrier
Summary: Patients with advanced gastric adenocarcinoma undergoing gastrectomy and HIPEC with or without CR are at high risk of malnutrition. Post-operative weight loss has a negative impact on patient outcomes.
Article
Oncology
A. Arjona-Sanchez, A. Martinez-Lopez, M. T. Moreno-Montilla, J. Mulsow, P. Lozano-Lominchar, B. Martinez-Torres, B. Rau, E. Canbay, A. Sommariva, M. Milione, M. Deraco, O. Sgarbura, A. Torgunrud, V. Kepenekian, N. J. Carr, A. Hoorens, J. B. Delhorme, R. Wernert, D. Goere, L. Martin-Roman, S. Cosyns, K. Flatmark, B. Davidson, L. Khellaf, F. Pereira-Perez, L. Rodriguez-Ortiz, A. Ibanez-Costa, A. Romero-Ruiz
Summary: This study validates the classification of pseudomyxoma peritonei (PMP), dividing it into two subcategories that can predict the survival and disease-free survival rates of patients. The inclusion of the Ki67 proliferation index in the pathology report for these patients is shown to be significant.
Article
Oncology
Bahar Canbay Torun, Olivier Glehen, Vahan Kepenekian, Armando Sardi, Alvaro Arjona-Sanchez, Yutaka Yonemura, Shoma Barat, David Morris, John Spiliotis, Federico Coccolini, Antonio Sommariva, Adrian Bartos, Sayyed Raza, Kurt Vander Speteen, Levhi Akin, Tulay Irez, Emel Canbay
Summary: The purpose of this study was to evaluate outcome data after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis originating from advanced epithelial ovarian carcinoma (PMOC). The study found that this treatment strategy can be safely performed with acceptable morbidity and mortality in specialized units.
Review
Oncology
Vahan Kepenekian, Olivia Sgarbura, Frederic Marchal, Laurent Villeneuve, Olivier Glehen, Shigeki Kusamura, Marcello Deraco
Summary: The prognosis of diffuse malignant peritoneal mesothelioma (DMPM) can be improved by combining cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). This study reviewed multiple protocols of HIPEC treatment for DMPM, and found that cisplatin, combined with doxorubicin, was the most commonly recommended drug regimen. Comparative studies showed that a bi-drug regimen led to better long-term oncologic outcomes. However, further comparative studies and protocol harmonization are needed to optimize HIPEC regimen choice.
INDIAN JOURNAL OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Charles Buiron, Remi Grange, Pascal Rousset, Laurent Villeneuve, Nazim Benzerdjeb, Olivier Glehen, Vahan Kepenekian
Summary: Hepatoid adenocarcinoma (HAC) is a rare disease that can develop from any thoraco-abdominal organ and exhibits features similar to hepatocellular carcinoma (HCC). Diagnosis and treatment of this disease pose significant challenges. So far, there have been 12 reported cases of primary peritoneal HAC with poor prognosis and diverse management. This article presents two additional cases managed in a multidisciplinary manner at an expert center, using a comprehensive approach including complete cytoreductive surgeries, hyperthermic intra-peritoneal chemotherapy (HIPEC), and limited systemic chemotherapy sequences. The use of choline PET-CT scan guided surgical exploration resulted in complete resection. The oncologic outcomes were promising, with one patient surviving 111 months after diagnosis and the other still alive at 43 months.
INDIAN JOURNAL OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Vahan Kepenekian, Olivia Sgarbura, Frederic Marchal, Laurent Villeneuve, Shigeki Kusamura, Marcello Deraco
Summary: Through an international consensus, it was confirmed that hyperthermic intraperitoneal chemotherapy (HIPEC) following complete cytoreductive surgery (CRS) is the first-line treatment for diffuse malignant peritoneal mesothelioma (DMPM), and the combination of cisplatin and doxorubicin is recommended as the preferred HIPEC regimen.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Meeting Abstract
Oncology
Pauline Corbaux, Benoit You, Vahan Kepenekian, Naoual Bakrin, Audrey Gelot, David Dayde, Christophe Sajous, Michele Lamuraglia, Julien Peron, Olivier Glehen, Gilles Freyer
ANTICANCER RESEARCH
(2023)